Nitrogen-containing heterocycle derivatives substituted with...

Details Nitrogen-containing heterocycle derivatives substituted with... Nitrogen-containing heterocycle derivatives substituted with...

2011-05-03

2011-05-03

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S359000, C548S217000

Reexamination Certificate

active

07935706

ABSTRACT:
It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.A compound represented by:wherein Z is N or CR1, A1is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rcand Rdare each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3and R4are each independently hydrogen, halogen, hydroxy etc., and R5is hydrogen or lower alkyl,or a pharmaceutically acceptable salt, or a solvate thereof.

REFERENCES:
patent: 3407199 (1968-10-01), Pachter
patent: 3538089 (1970-11-01), Schmidt et al.
patent: 4455422 (1984-06-01), Banno et al.
patent: 4960778 (1990-10-01), Lesieur et al.
patent: 5283242 (1994-02-01), Ellingboe
patent: 5576318 (1996-11-01), Bietti et al.
patent: 5948784 (1999-09-01), Fujiwara et al.
patent: 6352981 (2002-03-01), Treiber et al.
patent: 2005/0124627 (2005-06-01), Schadt et al.
patent: 460 016 (1968-07-01), None
patent: 460 017 (1968-07-01), None
patent: 102 48 067 (2004-04-01), None
patent: 102 48 925 (2004-04-01), None
patent: 0 296 560 (1988-12-01), None
patent: 0 367 141 (1990-05-01), None
patent: 0 903 349 (1999-03-01), None
patent: 1 484 327 (2004-12-01), None
patent: 1 251 128 (2006-12-01), None
patent: 2-169569 (1990-06-01), None
patent: 2003-212868 (2003-07-01), None
patent: WO 86/00899 (1986-02-01), None
patent: WO 99/61426 (1999-12-01), None
patent: WO 01/32634 (2001-05-01), None
patent: WO 01/56974 (2001-08-01), None
patent: WO 01/07436 (2001-12-01), None
patent: WO 02/16349 (2002-02-01), None
patent: WO 02/34718 (2002-05-01), None
patent: WO 02/40466 (2002-05-01), None
patent: WO 02/051806 (2002-07-01), None
patent: WO 02/068409 (2002-09-01), None
patent: WO 02/080928 (2002-10-01), None
patent: WO 03/010159 (2003-02-01), None
patent: WO 03/053366 (2003-07-01), None
patent: WO 03/057688 (2003-07-01), None
patent: WO 2004/046124 (2004-06-01), None
patent: WO 2004/087145 (2004-10-01), None
patent: WO 2004/100956 (2004-11-01), None
patent: WO 2004/103954 (2004-12-01), None
patent: WO 2005/019215 (2005-03-01), None
patent: WO 2005/080317 (2005-09-01), None
patent: WO 2006/008133 (2006-01-01), None
patent: WO 2006/010964 (2006-02-01), None
patent: WO 2006/010966 (2006-02-01), None
patent: WO 2006/010967 (2006-02-01), None
patent: WO 2006/010968 (2006-02-01), None
patent: WO 2006/010969 (2006-02-01), None
patent: WO 03/028728 (2006-04-01), None
patent: WO 2006/055187 (2006-05-01), None
patent: WO 2006/058338 (2006-06-01), None
patent: WO 2006/058753 (2006-06-01), None
patent: WO 2006/090272 (2006-08-01), None
patent: WO 2006/090273 (2006-08-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 and 365.
International Search Report of PCT/JP2007/053166.
Caroti et al. “Synthesis, Antilipidemic and Platelet Antiaggregatory Activity of 2-Aminobenzimidazole Amide Derivatives”. II Farmaco, vol. 44(3), 1989, pp. 227-225.
{hacek over (S)}ukalović et al. “Synthesis, dopamine D2receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs”. European Journal of Medicinal Chemistry, vol. 40, 2005, pp. 481-493.
Yous et al. “Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds”. Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 20(6), Dec. 2005, pp. 525-532.
Abadi. “Phenylpiperazinylmethylheterocycle Derivatives: Synthesis and Dopamine Receptor Binding Profiles”. Arch. Pharm. Pharm. Med. Chem, vol. 337, 2004, pp. 383-390.
Tomić et al. “Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential”. Bioorganic & Medicinal Chemistry Letters, vol. 14, 2004, pp. 4263-4266.
Keiser et al. “Evaluation of quinolone derivatives for antitrypanosomal activity.” Tropical Medicine and International Health, vol. 6(5), May 2001, pp. 369-389.
Roglic et al. “Introduction of a methyl group in α- or β-position of 1-heteroarylethyl-4-phenyl-piperazines affects their dopaminergic/serotonergic properties”. Arch. Pharm. Pharm. Med. Chem., vol. 334, 2001, pp. 375-380.
Shankhar et al. “Optically active antifungal azoles: synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]-ethyl}-tetrazol-2-yl/1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol”. Bioorganic & Medicinal Chemistry Letters, vol. 12, 2004, pp. 2225-2238.
Loren et al. “The Banert Cascade: A synthetic Sequence to PolyfunctionalNH-1,2,3-Triazoles”. Synthesis, 2005 No. 9, pp. 1514-1520.
Krasavin et al. “Synthesis and Practical Use of1H-1,2,3-Benzotriazole-5-carboxaldehyde for Reductive Amination”, Synthetic Communications, vol. 35, 2005, 2587-2595.
Prauda et al. “Unexpected Formation of 1,2-Dihydro-2-azolyl- and azubylisoquino-lines by the reduction of the Corresponding Isoquinolunuim Salts with Sodium Borohydride in Methanol”. J. Heterocyclic Chem, vol. 41, Nov.-Dec. 2004, pp. 915-929.
Cecchetti et al. (1,4-Benzothiazinyloxy) alkylpiperazine Derivatives as Potentiqal Antihypertensive Agents:. Bioorganic & Medicinal Chemistry Letters, vol. 10, 2000, pp. 465-468.
Borza et al. “Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists”. Bioorganic & Medicinal Chemistry Letters, vol. 16, 2006, pp. 4638-4640.
Borza et al. “Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists”. Bioorganic & Medicinal Chemistry Letters, vol. 17, 2007, pp. 406-409.
Borza et al. “Selective MR1/2BN-Mehtyl-D-aspartate Receptor Antagonists among Indole-2-carboxamides and Benzimidazole-2-carboxamides”. J. Med. Chem, vol. 50, 2007, pp. 901-914.
Broza et al. “New Benzoyl ureqa derivatives as a novel NR2B selective NMDA receptor antagonists”. Pharmazie, vol. 61(9), 2006, 799-800.
Bonte et al., “Amino ketone and amino alcohol derivatives of benzoxazolinone: synthesis, adrenergic and antihypertensive properties”, European Journal of Medical Chemistry, vol. 25, No. 4, May 1, 1990, pp. 361-368.

Affiliated with

Also associated with

Rating

Nitrogen-containing heterocycle derivatives substituted with... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nitrogen-containing heterocycle derivatives substituted with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-containing heterocycle derivatives substituted with... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2664629